ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2024-4-4-34-42ppan-120Research ArticleREVIEWThe Role of Pharmacogenetic Testing in Optimizing Antipsychotic TherapyOtmakhovA. P.

Andrey P. Otmakhov

126 Moika River Emb., St. Petersburg 190121

2 Akkuratov St., St. Petersburg, 197341

otmakhov_a@mail.ruProydinaD. S.

Darya S. Proydina

2 Akkuratov St., St. Petersburg, 197341

KibirovaA. Y.

Alexandra Y. Kibirova

126 Moika River Emb., St. Petersburg 190121

Litovskaya St., 2, Saint Petersburg, 194100

KidyaevaA. V.

Alla V. Kidyaeva

126 Moika River Emb., St. Petersburg 190121

3 Bekhterev St., St. Petersburg 192019

NasyrovaR. F.

Regina F. Nasyrova

3 Bekhterev St., St. Petersburg 192019

St. Petersburg State Psychiatric Hospital Sviatogo Nikolaya Chudotvortsa; Department of Psychiatry and Psychotherapy with Clinic, Almazov National Medical Research CenterRussian FederationDepartment of Psychiatry and Psychotherapy with Clinic, Almazov National Medical Research CenterRussian FederationSt. Petersburg State Psychiatric Hospital Sviatogo Nikolaya Chudotvortsa; Department of Psychiatry and Narcology, Saint Petersburg State Pediatric Medical UniversityRussian FederationSt. Petersburg State Psychiatric Hospital Sviatogo Nikolaya Chudotvortsa; Institute of Personalized Psychiatry and Neurology, Shared Use Center, V.M. Bekhterev National Medical Research Center for Psychiatry and NeurologyRussian FederationInstitute of Personalized Psychiatry and Neurology, Shared Use Center, V.M. Bekhterev National Medical Research Center for Psychiatry and NeurologyRussian Federation202418122024443442Copyright © Otmakhov A.P., Proydina D.S., Kibirova A.Y., Kidyaeva A.V., Nasyrova R.F., 20242024Otmakhov A.P., Proydina D.S., Kibirova A.Y., Kidyaeva A.V., Nasyrova R.F.Otmakhov A.P., Proydina D.S., Kibirova A.Y., Kidyaeva A.V., Nasyrova R.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/120

Antipsychotic therapy in psychiatric practice can last from several months to many years, which requires the selection of drugs with the greatest effectiveness and the lowest risk of adverse drug reactions for the patient. According to experts, about a quarter of the total variability in response to antipsychotics is of genetic origin. This review analyzes and summarizes the results of domestic and foreign studies of the role of hereditary risk factors that cause a decrease in hepatic metabolism and efflux of antipsychotics due to polymorphism of genes encoding cytochrome P450 isoenzymes and transporter proteins. The key enzymes of antipsychotic metabolism registered for use in Russia and abroad are presented. The prospects of various options for pharmacogenetic testing in reducing the risk of potentially fatal complications in the selection of antipsychotic therapy in clinical practice are assessed.

pharmacogenetic testingantipsychoticclassificationpharmacokineticscytochrometransporterp-glycoproteinpsychopharmacotherapyReferencesKidyaeva, A.V.; Nasyrova, R.F. The role of cariprazine in the prevention and correction of antipsychotic-induced cardiometabolic disorders. Сurrent Therapy of Mental Disorders. 2024, 3:51-57. https://doi.org/10.21265/PSYPH.2024.75.87.005Kidyaeva, A.V.; Nasyrova, R.F. The role of cariprazine in the prevention and correction of antipsychotic-induced cardiometabolic disorders. Сurrent Therapy of Mental Disorders. 2024, 3:51-57. https://doi.org/10.21265/PSYPH.2024.75.87.005Nasyrova, R.F.; Kidyaeva, A.V.; Grechkina, V.V.; Shnayder, N.A. Personalized approach to prediction and prevention of haloperidol-induced QT interval prolongation: brief review. Pharmacogenetics and Pharmacogenomics. 2024, 1:20-30. https://doi.org/10.37489/2588-0527-2024-1-20-30Nasyrova, R.F.; Kidyaeva, A.V.; Grechkina, V.V.; Shnayder, N.A. Personalized approach to prediction and prevention of haloperidol-induced QT interval prolongation: brief review. Pharmacogenetics and Pharmacogenomics. 2024, 1:20-30. https://doi.org/10.37489/2588-0527-2024-1-20-30Pashkovskiy, V.E.; Sofronov, A.G.; Kolchev, S.A.; et al. Prediction of repeated hospitalizations in a psychiatric hospital for patients with paranoid schizophrenia. V.M. Bekhterev review of psychiatry and medical psychology. 2019, 1:34-44. https://doi.org/10.31363/2313-7053-2019-1-34-44 (In Russ.)Pashkovskiy, V.E.; Sofronov, A.G.; Kolchev, S.A.; et al. Prediction of repeated hospitalizations in a psychiatric hospital for patients with paranoid schizophrenia. V.M. Bekhterev review of psychiatry and medical psychology. 2019, 1:34-44. https://doi.org/10.31363/2313-7053-2019-1-34-44 (In Russ.)Sorokin, M.Y.; Lutova, N.B.; Wied, V.D. Antipsychotic selection strategies: the need for a holistic approach. Zh Nevrol Psikhiatr Im S S Korsakova. 2022, 122(2):73-79. https://doi.org/10.17116/jnevro202212201273 (In Russ.)Sorokin, M.Y.; Lutova, N.B.; Wied, V.D. Antipsychotic selection strategies: the need for a holistic approach. Zh Nevrol Psikhiatr Im S S Korsakova. 2022, 122(2):73-79. https://doi.org/10.17116/jnevro202212201273 (In Russ.)Abritalin, E.U.; Aleksandrovsky, Yu.A.; Ananieva, N.I.; et al. Psychiatry: a national guide. Moscow: GEOTAR-Media, 2018. EDN: YMILDU (In Russ.)Abritalin, E.U.; Aleksandrovsky, Yu.A.; Ananieva, N.I.; et al. Psychiatry: a national guide. Moscow: GEOTAR-Media, 2018. EDN: YMILDU (In Russ.)Wunderink, L. Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Ther Adv Psychopharmacol. 2019, 9:2045125319836566. https://doi.org/10.1177/2045125319836566Wunderink, L. Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Ther Adv Psychopharmacol. 2019, 9:2045125319836566. https://doi.org/10.1177/2045125319836566Nasyrova, R.F.; Vaiman, E.E.; Repkina, V.V.; et al. Single-nucleotide polymorphisms as biomarkers of antipsychotic-induced akathisia: systematic review. Genes. 2023, 14(3). https://doi.org/10.3390/genes14030616Nasyrova, R.F.; Vaiman, E.E.; Repkina, V.V.; et al. Single-nucleotide polymorphisms as biomarkers of antipsychotic-induced akathisia: systematic review. Genes. 2023, 14(3). https://doi.org/10.3390/genes14030616Vaiman, E.E.; Shnayder, N.A.; Zhuravlev, N.M.; et al. Genetic biomarkers of antipsychotic-induced prolongation of the QT interval in patients with schizophrenia. Int J Mol Sci. 2022, 23(24). https://doi.org/10.3390/ijms232415786Vaiman, E.E.; Shnayder, N.A.; Zhuravlev, N.M.; et al. Genetic biomarkers of antipsychotic-induced prolongation of the QT interval in patients with schizophrenia. Int J Mol Sci. 2022, 23(24). https://doi.org/10.3390/ijms232415786Khasanova, A.K.; Dobrodeeva, V.S.; Shnayder, N.A.; et al. Blood and urinary biomarkers of antipsychotic-induced metabolic syndrome. Metabolites. 2022, 12(8). https://doi.org/10.3390/metabo12080726Khasanova, A.K.; Dobrodeeva, V.S.; Shnayder, N.A.; et al. Blood and urinary biomarkers of antipsychotic-induced metabolic syndrome. Metabolites. 2022, 12(8). https://doi.org/10.3390/metabo12080726Mazo, G.E.; Yakovleva, Ya.V. Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects. V.M. Bekhterev review of psychiatry and medical psychology. 2024, 58(2):107-115. https://doi.org/10.31363/2313-7053-2024-2-972Mazo, G.E.; Yakovleva, Ya.V. Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects. V.M. Bekhterev review of psychiatry and medical psychology. 2024, 58(2):107-115. https://doi.org/10.31363/2313-7053-2024-2-972Sosin, D.N.; Zhuperin, A.A.; Moshevitin, S.Yu.; Burygina, L.A. New prospects for getting over treatment resistant schizophrenia using drugs with adrenergic mechanism of action. Current Therapy of Mental Disorders. 2023, 1:23–30. https://doi.org/10.21265/PSYPH.2023.37.73.003 (In Russ.)Sosin, D.N.; Zhuperin, A.A.; Moshevitin, S.Yu.; Burygina, L.A. New prospects for getting over treatment resistant schizophrenia using drugs with adrenergic mechanism of action. Current Therapy of Mental Disorders. 2023, 1:23–30. https://doi.org/10.21265/PSYPH.2023.37.73.003 (In Russ.)Drug-induced long QT syndrome in psychiatry and neurology / edited by R. F. Nasyrova, N. G. Neznanov, N. A. Shnayder, M. M. Petrova. SPb: DEAN Publishing Center, 2024. 592 pp. ISBN 978-5-6051473-9-8 (In Russ.)Drug-induced long QT syndrome in psychiatry and neurology / edited by R. F. Nasyrova, N. G. Neznanov, N. A. Shnayder, M. M. Petrova. SPb: DEAN Publishing Center, 2024. 592 pp. ISBN 978-5-6051473-9-8 (In Russ.)Nasyrova, R.F.; Kidyaeva, A.V.; Petrova, M.M.; Shnayder, N.A. Antipsychotic-induced QT prolongation and Torsade de Pointes in patients with mental disorders: A review. Saf Risk Pharmacother. 2024. https://doi.org/10.30895/2312-7821-2024-410 (In Russ.)Nasyrova, R.F.; Kidyaeva, A.V.; Petrova, M.M.; Shnayder, N.A. Antipsychotic-induced QT prolongation and Torsade de Pointes in patients with mental disorders: A review. Saf Risk Pharmacother. 2024. https://doi.org/10.30895/2312-7821-2024-410 (In Russ.)Lauschke, V.M.; Ingelman-Sundberg, M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019, 130:65-77. https://doi.org/10.1016/j.ejps.2019.01.024Lauschke, V.M.; Ingelman-Sundberg, M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019, 130:65-77. https://doi.org/10.1016/j.ejps.2019.01.024Lauschke, V.M.; Zhou, Y.; Ingelman-Sundberg, M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019, 197:122-152. https://doi.org/10.1016/j.pharmthera.2019.01.002Lauschke, V.M.; Zhou, Y.; Ingelman-Sundberg, M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019, 197:122-152. https://doi.org/10.1016/j.pharmthera.2019.01.002van Westrhenen, R.; Aitchison, K.J.; Ingelman-Sundberg, M.; Jukić, M.M. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020, 11:94. https://doi.org/10.3389/fpsyt.2020.00094van Westrhenen, R.; Aitchison, K.J.; Ingelman-Sundberg, M.; Jukić, M.M. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020, 11:94. https://doi.org/10.3389/fpsyt.2020.00094Clinical psychopharmacogenetics / edited by R.F. Nasyrova, N.G. Neznanov. – SPb: DEAN Publishing Center, 2020, 408 pp. ISBN 978-5-6043573-7-8 (In Russ.)Clinical psychopharmacogenetics / edited by R.F. Nasyrova, N.G. Neznanov. – SPb: DEAN Publishing Center, 2020, 408 pp. ISBN 978-5-6043573-7-8 (In Russ.)Dobrodeeva, V.S.; Tolmachev, M.Y.; Shnayder, N.A.; Nasyrova, R.F. Influence of single nucleotide variantof gene LEP (rs3828942) on antipsychotic-induced abnormalglucose metabolism in patients with schizophrenia. Сurrent Therapy of Mental Disorders. 2020,1:16-20. https://doi.org/10.21265/PSYPH.2020.37.30.002 (In Russ.)Dobrodeeva, V.S.; Tolmachev, M.Y.; Shnayder, N.A.; Nasyrova, R.F. Influence of single nucleotide variantof gene LEP (rs3828942) on antipsychotic-induced abnormalglucose metabolism in patients with schizophrenia. Сurrent Therapy of Mental Disorders. 2020,1:16-20. https://doi.org/10.21265/PSYPH.2020.37.30.002 (In Russ.)Grunina, M.N.; Zabotina, A.M.; Zhuravlev, A.S.; et al. Dopamine receptor d2 (drd2) in peripheral blood lymphocytes as biomarker of response to antipsychotic medication. Sci Notes P Pavlov St Petersbg State Med Univ. 2020, 27(1):45-56. https://doi.org/10.24884/1607-4181-2020-27-1-45-56 (In Russ.)Grunina, M.N.; Zabotina, A.M.; Zhuravlev, A.S.; et al. Dopamine receptor d2 (drd2) in peripheral blood lymphocytes as biomarker of response to antipsychotic medication. Sci Notes P Pavlov St Petersbg State Med Univ. 2020, 27(1):45-56. https://doi.org/10.24884/1607-4181-2020-27-1-45-56 (In Russ.)Nasyrova, R.F.; Khasanova, A.K.; Altynbekov, K.S.; et al. The role of D-serine and D-aspartate in the pathogenesis and therapy of treatment-resistant schizophrenia. Nutrients. 2022, 14(23). https://doi.org/10.3390/nu14235142Nasyrova, R.F.; Khasanova, A.K.; Altynbekov, K.S.; et al. The role of D-serine and D-aspartate in the pathogenesis and therapy of treatment-resistant schizophrenia. Nutrients. 2022, 14(23). https://doi.org/10.3390/nu14235142Moskaleva, P.V.; Shnayder, N.A.; Dmitrenko, D.V.; et al. Association of TPH1 and TPH2 gene polymorphisms with the risk of developing psychoneurological disorders. Neurosci Behav Physiol. 2022, 52(3):462-469. https://doi.org/10.1007/s11055-022-01260-0Moskaleva, P.V.; Shnayder, N.A.; Dmitrenko, D.V.; et al. Association of TPH1 and TPH2 gene polymorphisms with the risk of developing psychoneurological disorders. Neurosci Behav Physiol. 2022, 52(3):462-469. https://doi.org/10.1007/s11055-022-01260-0Vaiman, E.E.; Tumova, M.A.; Guseinova, Z.T.; et al. Influence of single nucleotide polymorphisms of the serotonergic system genes on the occurrence of therapeutic resistance manifestations in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2023, 1 (118):41-49. https://doi.org/10.26617/1810-3111-2023-1(118)-41-49Vaiman, E.E.; Tumova, M.A.; Guseinova, Z.T.; et al. Influence of single nucleotide polymorphisms of the serotonergic system genes on the occurrence of therapeutic resistance manifestations in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2023, 1 (118):41-49. https://doi.org/10.26617/1810-3111-2023-1(118)-41-49Kaydan, M.A.; Zakharova, N.V.; Zorkina, Ya.A.; Kostyuk, G.P. Search for association of polymorphisms 23.rs6280 of the DRD3 gene, rs4680 of the COMT gene, rs6265 of the gene BDNF with schizophrenia resistant to antipsychotic therapy in Russian populations. Psikhiatriya. 2023, 21(7):14-23. https://doi.org/10.30629/2618-6667-2023-21-7-14-23Kaydan, M.A.; Zakharova, N.V.; Zorkina, Ya.A.; Kostyuk, G.P. Search for association of polymorphisms 23.rs6280 of the DRD3 gene, rs4680 of the COMT gene, rs6265 of the gene BDNF with schizophrenia resistant to antipsychotic therapy in Russian populations. Psikhiatriya. 2023, 21(7):14-23. https://doi.org/10.30629/2618-6667-2023-21-7-14-23Varnai, R.; Szabo, I.; Tarlos, G.; et al. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Pharmacogenomics J. 2020, 20(3):380-387. https://doi.org/10.1038/s41397-019-0123-zVarnai, R.; Szabo, I.; Tarlos, G.; et al. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Pharmacogenomics J. 2020, 20(3):380-387. https://doi.org/10.1038/s41397-019-0123-zKostyuk, G.P.; Zakharova, N.V.; Reznik, A.M.; et al. Perspectives of the use of pharmacogenetic tests in neurology and psychiatry. Zh Nevrol Psikhiatr Im S S Korsakova. 2019, 119(9):131-135. https://doi.org/10.17116/jnevro2019119091131Kostyuk, G.P.; Zakharova, N.V.; Reznik, A.M.; et al. Perspectives of the use of pharmacogenetic tests in neurology and psychiatry. Zh Nevrol Psikhiatr Im S S Korsakova. 2019, 119(9):131-135. https://doi.org/10.17116/jnevro2019119091131Zeier, Z.; Carpenter, L.L.; Kalin, N.H.; et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018, 175(9):873-886. https://doi.org/10.1176/appi.ajp.2018.17111282Zeier, Z.; Carpenter, L.L.; Kalin, N.H.; et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018, 175(9):873-886. https://doi.org/10.1176/appi.ajp.2018.17111282Zhuravlev, N.M.; Otmachov, A.P.; Bartasinskaya, A.E. Clinical case of a 36-year-old patient with paranoid schizophrenia and drug-induced QT prolongation. Personalized Psychiatry and Neurology. 2022, 2(2):78-83. https://doi.org/10.52667/2712-9179-2022-2-2-78-83Zhuravlev, N.M.; Otmachov, A.P.; Bartasinskaya, A.E. Clinical case of a 36-year-old patient with paranoid schizophrenia and drug-induced QT prolongation. Personalized Psychiatry and Neurology. 2022, 2(2):78-83. https://doi.org/10.52667/2712-9179-2022-2-2-78-83Tonk, E.C.M.; Gurwitz, D.; Maitland-van der Zee, A.H.; Janssens, A.C.J.W. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017, 17(4):386-392. https://doi.org/10.1038/tpj.2016.34Tonk, E.C.M.; Gurwitz, D.; Maitland-van der Zee, A.H.; Janssens, A.C.J.W. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017, 17(4):386-392. https://doi.org/10.1038/tpj.2016.34Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of antipsychotics. Encyclopedia (Basel, 2021). 2022, 2(2):974-989. https://doi.org/10.3390/encyclopedia2020064Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of antipsychotics. Encyclopedia (Basel, 2021). 2022, 2(2):974-989. https://doi.org/10.3390/encyclopedia2020064Shnayder, N.A.; Khasanova, A.K.; Nasyrova, R.F. First phase of antipsychotic metabolism in the liver: the role of oxidation. Fgen_Fgenom. 2023, (1):15-30. https://doi.org/10.37489/2588-0527-2022-1-15-30Shnayder, N.A.; Khasanova, A.K.; Nasyrova, R.F. First phase of antipsychotic metabolism in the liver: the role of oxidation. Fgen_Fgenom. 2023, (1):15-30. https://doi.org/10.37489/2588-0527-2022-1-15-30Carrascal-Laso, L.; Isidoro-García, M.; Ramos-Gallego, I.; Franco-Martín, M.A. Review: influence of the CYP450 genetic variation on the treatment of psychotic disorders. J Clin Med Res. 2021, 10(18):4275. https://doi.org/10.3390/jcm10184275Carrascal-Laso, L.; Isidoro-García, M.; Ramos-Gallego, I.; Franco-Martín, M.A. Review: influence of the CYP450 genetic variation on the treatment of psychotic disorders. J Clin Med Res. 2021, 10(18):4275. https://doi.org/10.3390/jcm10184275Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87Drugbank. Accessed on 10 October 2024. https://go.drugbank.comDrugbank. Accessed on 10 October 2024. https://go.drugbank.comState Register of Medicines. Accessed on 7 October 2024. https://grls.rosminzdrav.ru/Default.aspxState Register of Medicines. Accessed on 7 October 2024. https://grls.rosminzdrav.ru/Default.aspxVasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry. 2022, 13:1069432. https://doi.org/10.3389/fpsyt.2022.1069432Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry. 2022, 13:1069432. https://doi.org/10.3389/fpsyt.2022.1069432Popovic, D.; Nuss, P.; Vieta, E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015, 14:15. https://doi.org/10.1186/s12991-015-0053-3Popovic, D.; Nuss, P.; Vieta, E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015, 14:15. https://doi.org/10.1186/s12991-015-0053-3Preda, A.; Shapiro, B.B. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020, 19(12):1529-1538. https://doi.org/10.1080/14740338.2020.1832990Preda, A.; Shapiro, B.B. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020, 19(12):1529-1538. https://doi.org/10.1080/14740338.2020.1832990Zhao, M.; Ma, J.; Li, M.; et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021, 22(23). https://doi.org/10.3390/ijms222312808Zhao, M.; Ma, J.; Li, M.; et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021, 22(23). https://doi.org/10.3390/ijms222312808Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87Alemayehu, D.; Melisie, G.; Taye, K.; et al. The role of ABC efflux transporter in treatment of pharmaco-resistant schizophrenia: a review article. Clin Pharmacol Biopharm. 2019, 8:189Alemayehu, D.; Melisie, G.; Taye, K.; et al. The role of ABC efflux transporter in treatment of pharmaco-resistant schizophrenia: a review article. Clin Pharmacol Biopharm. 2019, 8:189Qosa, H.; Miller, D.S.; Pasinelli, P.; Trotti, D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015, 1628(Pt B):298-316. https://doi.org/10.1016/j.brainres.2015.07.005Qosa, H.; Miller, D.S.; Pasinelli, P.; Trotti, D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015, 1628(Pt B):298-316. https://doi.org/10.1016/j.brainres.2015.07.005Wijaya, J.; Fukuda, Y.; Schuetz, J.D. Obstacles to brain tumor therapy: key ABC transporters. Int J Mol Sci. 2017, 18(12). https://doi.org/10.3390/ijms1812254445Wijaya, J.; Fukuda, Y.; Schuetz, J.D. Obstacles to brain tumor therapy: key ABC transporters. Int J Mol Sci. 2017, 18(12). https://doi.org/10.3390/ijms1812254445Nasyrova, R.F.; Shnayder, N.A.; Osipova, S.M.; et al. Genetic predictors of antipsychotic efflux impairment via blood-brain barrier: role of transport proteins. Genes. 2023, 14(5). https://doi.org/10.3390/genes14051085Nasyrova, R.F.; Shnayder, N.A.; Osipova, S.M.; et al. Genetic predictors of antipsychotic efflux impairment via blood-brain barrier: role of transport proteins. Genes. 2023, 14(5). https://doi.org/10.3390/genes14051085Luptáková, D.; Vallianatou, T.; Nilsson, A.; et al. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021, 26(12):7732-7745. https://doi.org/10.1038/s41380-021-01267-yLuptáková, D.; Vallianatou, T.; Nilsson, A.; et al. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021, 26(12):7732-7745. https://doi.org/10.1038/s41380-021-01267-yPharmGKB. Accessed on October 20, 2024. https://www.pharmgkb.org/gene/PA267/variantAnnotationPharmGKB. Accessed on October 20, 2024. https://www.pharmgkb.org/gene/PA267/variantAnnotationNasyrova, R.; Dobrodeeva, V.; Skopin, S.; et al. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery). 2020, (3):6-12. https://doi.org/10.33920/med-01-2003-01Nasyrova, R.; Dobrodeeva, V.; Skopin, S.; et al. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery). 2020, (3):6-12. https://doi.org/10.33920/med-01-2003-01Lara, D.V.; de Melo, D.O; de Silva, R.A.M.; de Santos, P.C.J.L. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021, 22(8):505-513. https://doi.org/10.2217/pgs-2020-0187Lara, D.V.; de Melo, D.O; de Silva, R.A.M.; de Santos, P.C.J.L. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021, 22(8):505-513. https://doi.org/10.2217/pgs-2020-0187Yagudina, R.I.; Serpik, V.G.; Babiy, V.V.; Ugrekhelidze, D.T. Сriteria of efficiency in pharmacoeconomic analysis. Pharmacoeconomics Theory Pract. 2017, 5(3):11-15. https://doi.org/10.30809/phe.3.2017.7Yagudina, R.I.; Serpik, V.G.; Babiy, V.V.; Ugrekhelidze, D.T. Сriteria of efficiency in pharmacoeconomic analysis. Pharmacoeconomics Theory Pract. 2017, 5(3):11-15. https://doi.org/10.30809/phe.3.2017.7Morris, S.A.; Alsaidi, A.T.; Verbyla, A.; et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther. 2022, 112(6):1318-1328. https://doi.org/10.1002/cpt.2754Morris, S.A.; Alsaidi, A.T.; Verbyla, A.; et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther. 2022, 112(6):1318-1328. https://doi.org/10.1002/cpt.2754Kumar, A.; Kearney, A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021, 33(11):849-851. https://doi.org/10.1097/JXX.0000000000000666Kumar, A.; Kearney, A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021, 33(11):849-851. https://doi.org/10.1097/JXX.0000000000000666Adiukwu, F.; Adesokun, O.; Essien, E.; et al. Pharmacogenetic testing in psychiatry: Perspective on clinical utility. Asian J Psychiatr. 2023, 86:103674. https://doi.org/10.1016/j.ajp.2023.103674Adiukwu, F.; Adesokun, O.; Essien, E.; et al. Pharmacogenetic testing in psychiatry: Perspective on clinical utility. Asian J Psychiatr. 2023, 86:103674. https://doi.org/10.1016/j.ajp.2023.103674Bousman, C.A.; Bengesser, S.A.; Aitchison, K.J.; et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021, 54(1):5-17. https://doi.org/10.1055/a-1288-1061Bousman, C.A.; Bengesser, S.A.; Aitchison, K.J.; et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021, 54(1):5-17. https://doi.org/10.1055/a-1288-1061Maruf, A.A.; Fan, M.; Arnold, P.D.; et al. Pharmacogenetic testing options relevant to psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry. 2020, 65(8):521-530. https://doi.org/10.1177/0706743720904820Maruf, A.A.; Fan, M.; Arnold, P.D.; et al. Pharmacogenetic testing options relevant to psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry. 2020, 65(8):521-530. https://doi.org/10.1177/0706743720904820

The authors declare that there are no conflicts of interest present.